Annualized Rate of all Infections [Time Frame: Up to Week 121]
Annualized Rate of Acute Serious Bacterial Infections (ASBIs) [Time Frame: Up to Week 121]
Annualized Rate of Episodes of Fever [Time Frame: Up to Week 121]
Time to First ASBI [Time Frame: Up to Week 121]
Duration of Infections [Time Frame: Up to Week 121]
Number of Participants With Positive Binding Antibodies and Neutralizing Antibodies to rHuPH20 [Time Frame: Up to Week 121]
Trough Level of Total IgG [Time Frame: Up to Week 121]
Doses of TAK-881 [Time Frame: Up to Week 121]
Treatment Interval of TAK-881 [Time Frame: Up to Week 121]
Number of Infusions Per Month With Investigational Medical Device Using TAK-881 [Time Frame: Up to Week 121]
Number of Infusions Sites (Needle Sticks) per Month With Investigational Medical Device Using TAK-881 [Time Frame: Up to Week 121]
Number of Infusions Sites (Needle Sticks) per infusion With Investigational Medical Device Using TAK-881 [Time Frame: Up to Week 121]
Duration of Infusions (minutes) With Investigational Medical Device Using TAK-881 [Time Frame: Up to Week 121]
Monthly Infusion Time (minutes/month) With Investigational Medical Device Using TAK-881 [Time Frame: Up to Week 121]
Maximum Tolerated Infusion Rate per Site (milliliter/hour/site) With Investigational Medical Device Using TAK-881 [Time Frame: Up to Week 121]
Infusion Volume per Site (milliliter/site) With Investigational Medical Device Using TAK-881 [Time Frame: Up to Week 121]
Number of Participants who have Infusions of TAK-881 at Physical Location [Time Frame: Up to Week 121]
Number of Participants, Caregiver, or Healthcare Professional (HCP) who have Administration of TAK-881 [Time Frame: Up to Week 121]
Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scores in Participants Aged >=16 Years [Time Frame: From Week 13 up to Week 121]
Health-Related Quality of Life (HRQoL): EuroQol 5 Dimension 5 Level Questionnaire (EQ-5D-5L) Score in Participants Aged >=12 Years [Time Frame: From Baseline up to Week 121]
Treatment Preference Measured by a Disease-specific Questionnaire for Participants and the Investigational Medical Device Using TAK-881 in Participants Aged >=12 Years [Time Frame: At Weeks 25 and 73]
Number of Days not Able to go to School, Work, Daycare, or to Perform Normal Daily Activities Due to Infections and/or their Treatment or Other Illnesses [Time Frame: Up to Week 121]
Number of Days on Antibiotics [Time Frame: Up to Week 121]
Number of Hospitalizations With Indications (Infection or other Illnesses) [Time Frame: Up to Week 121]
Number of Days of Hospitalization [Time Frame: Up to Week 121]
Number of Acute Physician Visits Due to Infection or Other Illnesses [Time Frame: Up to Week 121]
Infusion Preparation Time For TAK-881 by HCP [Time Frame: Up to Week 121]
Infusion Preparation Time For TAK-881 by Participants/Caregiver [Time Frame: Up to Week 121]
Number of Participants With Adverse Events (AEs) Related to the Investigational Medical Device [Time Frame: Up to Week 121]
